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worsened by their abuse and misuse in medicine and in 
farming (Marshall and Levy 2011; Laxminarayan et al. 
2013; Woolhouse et al. 2015). The antibiotic resistance 
problem is even more serious when considering that the 
development of novel antibiotic molecules is increasingly 
difficult and less profitable for pharmaceutical industry 
(Towse and Sharma 2011; Shlaes et al. 2013). Antibiotic 
resistance can also represent a threat to disease control; 
it complicates the patient management and  the treat-
ment strategy prolonging the hospital stays (Colomb-
Cotinat et al. 2016). Nowadays, this international public 
health problem is recognized as one of the scourges of 
the twenty-first century (WHO 2015). The causes of this 
broad diffusion of multidrug bacteria are widely accepted, 
for example, the overuse and inappropriate use of antibi-
otics for nonbacterial infections such as colds and other 
viral infections and inadequate antibiotic stewardship in 
the clinical arena and their use in animals as growth pro-
moters that can select resistant strains (Levy 2002). Dif-
ferent studies have sought to estimate the morbidity and 
mortality of infections due to multidrug-resistant bacteria 
(MDRB). The European Centre for Disease Prevention and 
Control (ECDC 2009) published a joint report based on 
data from 2007, estimating at about 386,000 the annual 
number of infections due to MDRB in Europe and with a 
number of deaths associated with these infections, which 
was estimated at more than 25,000. In another American 
report by the Centers for Disease Control and Preven-
tion (CDC 2013), it is reported an overview of the annual 
morbidity and mortality of antibiotic-resistant infections 
in the United States, estimating their number at approxi-
mately 2 million and the number of deaths associated with 
these infections at 23,000. These two studies underlined 
the importance of morbidity and mortality of antibiotic 
resistance on public health. Hospital environment plays a 
Abstract Bacterial antibiotic resistance is a natural phe-
nomenon, seriously affecting the treatment of infections. 
The biggest danger is that current antibiotics are not able 
to eradicate the resistant strains. In recent years, alternative 
antibacterial substances are being sought, which can help 
in these cases. Fatty acids and monoglycerides are known 
among the natural substances for their antimicrobial proper-
ties and, important detail, bacteria do not develop resistance 
to them. In this work, we studied the antimicrobial effects of 
a monoglyceride blend against some multi-resistant Entero-
cocci and Escherichia coli strains. Based on literature data, 
a blend of fatty acids and their monoglycerides was cre-
ated and its antimicrobial activity was evaluated against 37 
strains of E. coli and 17 Enterococci presenting resistance 
to at least two antibiotics. A different behavior was observed 
in the two groups of bacteria, proving that alternative sub-
stances can be considerate for the potential treatment of 
multidrug-resistant strains.
Keywords Multidrug resistance · Enterococci · E. coli · 
Monoglycerides · Antibacterial
Introduction
Bacterial resistance to antibiotics is a natural phenom-
enon, but the spreading of multidrug resistance has been 
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significant role in the occurrence of nosocomial infection 
since it harbors a diverse population of microorganisms 
(ECDC 2009). Bacterial pathogens of medical importance 
such as Escherichia coli, Enterococci, Pseudomonas aer-
uginosa and coagulase-negative Staphylococci are a com-
mon cause of healthcare-associated infection, which could 
be able to survive and persist for long periods in the hos-
pital environment. Enterococci and E. coli are two exam-
ples of organisms present in the gut of most animals and 
that have emerged as nosocomial and community-acquired 
pathogens for their ability to develop high-level resist-
ance to antimicrobials (Werner et al. 2012). Moreover, 
these bacteria are able to transfer their resistance genes 
by conjugation to other bacteria increasing the spread of 
MDRB. For these reasons, increasing interest is arising 
about alternative antibacterial products, especially those 
acting on bacterial targets, such as the bacterial membrane, 
that are less likely to develop mutations without hindering 
the survival of the bacterial cell (Gao et al. 2014). The 
class of compounds on which most studies are focusing 
are phytochemical compounds, antimicrobial peptides, 
and fatty acids (Hancock and Sahl 2006; Desbois 2012; 
Borges et al. 2015). Among the candidate replacements for 
antibiotics, the antibacterial activity of free fatty acids and 
their monoglycerides has been deeply studied by Jackman 
et al. (2016) since their non-specific mode of action could 
make them suitable for various applications not only in 
medicine, but also for the agri-food sector (Desbois 2012). 
Moreover, the development of bacterial resistance to these 
substances seems to be less likely in comparison with anti-
biotics, and it would be anyway less problematic (Desbois 
and Smith 2010; Schlievert and Peterson 2012). Among 
SCFAs and their monoglycerides, butyric acid couples 
antimicrobial activity with its important nutritional role 
for colonocytes (Namkung et al. 2011). Medium-chain 
fatty acids (MCFA) and their monoglycerides have also 
been recognized as potential antimicrobial molecules, both 
against Gram-positive and Gram-negative bacteria (Isaacs 
2005; Batovska et al. 2009; Umerska et al. 2016). Among 
this group, monolaurin, the monoglyceride of lauric acid, 
is the most powerful compound, being strongly active 
against Gram-positive bacteria and enveloped viruses 
(Strandberg et al. 2010; Schlievert and Peterson 2012). 
The main problem for the application of lauric acid and 
monolaurin it is their poor water solubility that has been 
addressed using emulsifiers or developing liposomic nano-
carriers or non-aqueous gels (Yang et al. 2009; Mueller 
and Schlievert 2015). Based on these previous studies, we 
created a blend (hereinafter referred to as BL) of emulsi-
fiers, free fatty acids and monoglycerides to broaden the 
spectrum of antimicrobial activity and obtain a substance 
that could make a stable mix with water up to certain con-
centrations. The antibacterial activity of the blend was 
tested against both Gram-positive and Gram-negative bac-
teria, in particular different E. coli and Enterococci, which 
are among the bacteria those that easily acquire antibiotic 
resistances and can cause infections in humans.
Materials and methods
Bacterial strains, growth media, and chemicals
The test strains, 37 Escherichia coli and 17 Enterococci 
(11 E. faecium and 6 E. faecalis), were isolated and identi-
fied from Public Hospital Sant’Agostino, Modena (Italy). 
These bacteria were selected for this study because they 
all presented multiple antibiotic resistances. Bacteria were 
maintained with 20% glycerol at −18 °C and revitalized 
and grown for the experiments in Tryptic Soy Broth (TSB-
Oxoid, Milan, Italy) for 18–24 h at 37 ± 1 °C. All com-
pounds utilized to create the antimicrobial blend BL were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
GC–MS characterization of BL
The composition of the blend of SCFA, MCFA and their 
esters (BL) was designed on literature bases and optimized 
in preliminary studies (data not shown). The composition 
of the final substance was analyzed by gas chromatography 
using a gas chromatograph GC2010 PLUS (KYT, Kyoto, 
Japan) and a Shimadzu mass spectrometer coupled to a sin-
gle quadrupole MS-QP2010 (KYT, Kyoto, Japan). GC–MS 
was equipped with an auto sampler HT280T (HTA srl, 
Brescia, Italy) to minimize operator mistakes. Samples were 
incubated in the auto sampler oven at 25 °C for 15 min. The 
injector of the GC heater was set at 270 °C. Volatile organic 
compounds were separated using an analytical capillary Col-
umn (5-MS capillary column, 30 m, 0.25 mm, 25 μm) and 
the carrier gas was ultrapure helium (99.99%) at a constant 
flow rate of 1.5 ml min−1. The injected volume was 1 μl with 
a split ratio of 100:1. The temperature program for the GC 
was configured as follows: starting temperature 50 °C for 
5 min, followed by a linear gradient 3 °C  min−1 to 220 °C 
and held for 5 min, with a source temperature of 180 °C. 
Compounds identification was performed by NIST library 
(Badoni et al. 2010).
Evaluation of antibiotic resistance of clinical isolates
The antimicrobials tested were ampicillin, piperacillin, 
meropenem, amikacin, cefotaxime and ciprofloxacin for 
Gram-negative bacteria and vancomycin, ciprofloxacin, 
teicoplanin, tetracycline, rifampin and erythromycin for 
Gram-positive bacteria. Antibiotic resistance was assessed 
by minimum inhibitory concentrations (MICs), according 
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to the Clinical Laboratory Standards Institute guidelines 
(CLSI 2012). The resistance and sensibility to antibiotics 
were defined by breakpoints according to European Com-
mittee on Antimicrobial Susceptibility Testing, Version 7.1 
(EUCAST 2017).
Evaluation of antimicrobial activity of BL
Antibacterial activity was evaluated on Tryptic Soy Agar 
(TSA- Oxoid, Milan) in which the substance was dissolved 
in different concentrations: (0.05, 0.1, 0.2, 0.4, 0.8%, 1, 1.1, 
1.2, 1.4, 1.6, 1.8 and 2%).
The bacteria were cultured overnight at 37 °C in TSB, 
then spotted with micro-diluter system on the surface of cul-
ture media containing the different concentration of blend 
of monoglycerides and incubated for 18–24 h at 37 ± 1 °C. 
After incubation, the minimum inhibitory concentration of 
the blend was evaluated against the tested strains.
Results
GC–MS analysis of BL
The composition of BL revealed by GC–MS is reported in 
Table 1. The 39.2% of the mixture is composed of mono-
glycerides of fatty acids, namely butyric, caprylic, capric, 
and lauric acid (C4, C8, C10 and C12, respectively). 
Another 13.1% is composed by free fatty acids. The remain-
ing 47.22% consist of glycerol and propylene glycol, used 
as emulsifiers.
Antibiotic resistance of selected strains
All the strains utilized in this study were resistant to at 
least two of the antibiotics tested. For what concerns E. 
coli isolates, five of them (13.89%) showed a double anti-
biotic resistance, two were resistant to three antibiotics 
(5.55%), thirteen strains (36.11%) possessed four resist-
ances, 11 strains (30.56%) had five resistances and the 
last five (13.89%) were resistant to all six antibiotics. The 
same description may apply to Enterococci: 11 isolates 
(64.71%) showed a double resistance, two strains (11.76%) 
were resistant to three antibiotics, three (17.65%) had four 
resistances and the last one (5.88%) was resistant to five 
antibiotics (data not shown).
Antimicrobial effect of BL
The antimicrobial activity of BL resulted higher for Gram-
positive bacteria than for Gram-negative bacteria. With 
regard to E. coli strains, the majority of them, 21 (58.3%) 
were inhibited by a concentration of 1.4% of the blend 
and the remaining strains were inhibited by concentrations 
between 1.1 and 1.6% About the Enterococci, all strains 
Table 1  Composition of BL by GC–MS analysis
Retention 
time (min)
Compound Quantity (% w/w)
4.62 Butyric acid 8.50
6.05 Propylene glycol 13.42
8.34 Glycerol 33.80
9.69 Capric acid 1.10
9.74 Monoglycerides of butyric acid 24.40
11.14 Lauric acid 3.50
12.08 Monoglycerides of caprylic acid 2.80
13.03 Monoglycerides of capric acid 3.60
13.89 Monoglycerides of lauric acid 8.40
Table 2  Minimum inhibitory concentration (MIC) of BL on the 
selected bacterial strains
E.c. Escherichia coli
Strain Conc. (%) Strain Conc. (%) Strain Conc. (%)
E.c. 8 1.40 E.c. 104 1.40 E. faecalis 7 0.10
E.c. 9 1.40 E.c. 27 1.40 E. faecium 19 0.10
E.c. 12 1.40 E.c. 13 1.40 E. faecium 61 0.10
E.c. 18 1.40 E.c. 15 1.40 E. faecium 
108
0.20
E.c. 25 1.20 E.c. 26 1.40 E. faecium 
110
0.40
E.c. 28 1.40 E.c. 27 1.40 E. faecium 
112
0.40
E.c. 29 1.40 E.c. 34 1.10 E. faecium 
113
0.40
E.c. 30 1.10 E.c. 37 1.10 E. faecalis 
12A
0.20
E.c. 42 1.40 E.c. 40 1.40 E. faecium 
A29
0.20
E.c. 53 1.10 E.c. 41 1.60 E. faecalis 
A30
0.20
E.c. 54 1.10 E.c. 43 1.40 E. faecium 
B20
0.20
E.c. 56 1.20 E.c. 46 1.40 E. faecium B5 0.40
E.c. 63 1.40 E.c. 60 1.40 E. faecium 
B62
0.40
E.c. 70 1.10 E.c. 64 1.40 E. faecium 
MR3
0.40
E.c. 95 1.10 E.c. 65 1.40 E. faecalis 
RO1
0,10
E.c. 96 1.10 E.c. 101 1.10 E. faecalis 
RO2
0,20
E.c. 97 1.40 E.c. 105 1.20 E. faecalis 
RO4
0,10
E.c. 98 1.20 E.c. 107 1.40
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were inhibited by tested concentrations between 0.1 and 
0.4% (Table 2).
Discussion
It has been shown that fatty acids and their monoglycer-
ides are effective in inhibiting bacterial growth (Namkung 
et al. 2011). Salsali proposed that the antimicrobial activ-
ity of organic acids could be attributed to their ability to 
pass across the cell membrane and dissociate in the more 
alkaline cell, thereby acidifying the cell cytoplasm (Salsali 
et al. 2008).
The BL mix, used in this study, was created with the spe-
cific aim to couple the antimicrobial properties of C4, C8, 
and C10 fatty acids and monoglycerides against Gram-neg-
ative bacteria (Namkung et al. 2011; Umerska et al. 2016) 
to the efficacy of lauric acid and monolaurin on Gram-pos-
itive bacteria, fungi, and viruses (Strandberg et al. 2010; 
Mueller and Schlievert 2015). In particular, the efficacy of 
BL was studied against different Enterococci and some E. 
coli strains. The results obtained showed that BL mix had 
a strong activity against Gram-positive Enterococci, while 
only concentrations above 1% were able to inhibit the growth 
of Gram-negative E. coli strains. Batovska et al. (2009) 
reported that the activity against Gram-negative species 
could be enhanced by increasing the percentage of MCFAs, 
such as caproic and caprylic acid, or coupling the activity 
of monolaurin with chelating cations such as EDTA or cit-
rate. The utilization of products based on fatty acids and 
monoglycerides seems to be unrelated to the development of 
resistance against them (Schlievert and Peterson 2012) and 
it could even enhance the activity of traditional antibiotics 
against pathogens (Hess et al. 2014). The present mix or its 
optimized versions could be tested for their clinical applica-
tion as topical treatments or, after an evaluation about the 
gastric protection, as food supplements.
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